Seelos Therapeutics, Inc.: cash_and_restricted_cash

Value{"amount": 2996000, "concept": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "currency": "USD"}
Period (as of 2023-12-31)
Statuscurrent
EntitySeelos Therapeutics, Inc.
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference: 0001410578-24-000140 · Open the official SEC filing →
Retrieved: 2026-08-19T09:53:15.866234+02:00
Raw response sha256: f7bde1a401b286c74a2fd824ee1df541…
Also addressable by official identifiers: https://factanker.com/fact/sec/cik-0001017491/cash-and-restricted-cash/2023-12-31 (CIK, metric, reporting date)
Cite as: FACTANKER, https://factanker.com/fact/e8334a2a-53bd-42c3-a7c6-914d4e53c0fb

History

From the Record
32 US software companies haven’t lost money in a decade. One of them is steadier than all the rest.
Read the findingSearch 53 million companies